SCHEMBL23729020

SCHEMBL23729020

COC(=O)OCc1ccc(NC(=O)C(C)CCCCN)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 2/20 0.49
▸ HSD17B10 Q99714 1/20 0.44
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CA7 P43166 2/20 0.42
▸ CA14 Q9ULX7 2/20 0.42
▸ EPOR P19235 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ KLKB1 P03952 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ CPB1 P15086 1/20 0.38
▸ CPB2 Q96IY4 1/20 0.38
▸ KLK7 P49862 1/20 0.38
▸ NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25689671 0.79 HSD17B10 (0.48) HSD17B10CA1CA2CA7CA14
SCHEMBL21726052 0.76 CA1 (0.51) LTA4HCA1CA2KMT2AKLKB1
SCHEMBL24774255 0.75 LTA4H (0.49) LTA4HCA1CA2EPORHDAC2
SCHEMBL22299573 0.75 HSD17B10 (0.44) LTA4HHSD17B10CA1CA2CA7
SCHEMBL25148090 0.75 HSD17B10 (0.44) LTA4HHSD17B10CA1CA2CA7
SCHEMBL21263588 0.73 LTA4H (0.50) LTA4HCA1CA2HDAC2KLKB1
SCHEMBL21205411 0.73 HSD17B10 (0.43) HSD17B10CA1CA2CA7CA14
SCHEMBL21875528 0.73 HSD17B10 (0.46) HSD17B10CA1CA2CA7CA14
SCHEMBL17737202 0.73 HSD17B10 (0.52) HSD17B10MEN1KMT2AMAPTNPC1
SCHEMBL16418621 0.72 KLKB1 (0.49) LTA4HCA1CA2HDAC2KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11077201-B2 Immunoconjugates with an intracellularly-cleavable linkage IMMUNOMEDICS, INC. (US) 2021-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11077201-B2 Immunoconjugates with an intracellularly-cleavable linkage CD47, CD44, DNPEP LTA4H 2078/4885HSD17B10 2826/4885CA1 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback